Johnson & Johnson Prostate Cancer Drug Impresses
07:23 EDT 2 Jun 2012 | Forbes
New data on the prostate cancer drug Zytiga show it slows tumor growth and may improve survival.
Original Article: Johnson & Johnson Prostate Cancer Drug Impresses
More From BioPortfolio on "Johnson & Johnson Prostate Cancer Drug Impresses"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
